Teva Pharmaceutical has been experiencing market insecurities, with stock plummeting 14%, attributed to the firm’s own success and investor skepticism about its future. Despite this, various key investors, including
Bank of New York Mellon Corp,
Victory Capital Management Inc., and
Capital Wealth Planning LLC, have increased their stakes in Teva. Some executives, like
Eric Hughes and
Mark Sabag, have offloaded significant stock. This contrasts with intense buying activity exhibited by whales (major shareholders). A new forecast issued by
Bank of America paints a grim picture for the firm’s stock price. Notably, Teva scored a considerable victory with the Sanofi-Tied Drug which boosted its stock price by 26%.
Zacks Research and
UBS issued a pessimistic earnings forecast and increased the firm’s stock price target to $30, respectively. Barbays also uplifted Teva's stock target following its prognosis on sales potential. Certain analysts have predicted about 25.1% upside in Teva's stake. It's also worthwhile to consider that investing in Teva three years ago would have yielded a 138% gain.
Teva Pharmaceutical Stocks News Analytics from Wed, 08 May 2024 07:00:00 GMT to Sat, 08 Mar 2025 12:44:46 GMT -
Rating -4
- Innovation 3
- Information 6
- Rumor -6
